These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-002341-12 Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis Patients 2006-01-04 due-trials
Reported results 2004-002941-11 A multicentre, 3-month, randomised, double blind, placebo and active controlled study on the tolerability and efficacy of ZT-1 for the symptomatic treatment of mild to moderate Alzheimer’s Disease 2006-04-03 due-trials
Reported results 2006-000756-41 Estudio multicéntrico Fase IIa, aleatorizado, doble ciego, controlado con placebo de una semana de tratamiento con Depelestat en pacientes con síndrome de distrés respiratorio agudo Phase IIa multice... 2007-07-30 due-trials
Completed, but no date, and reported results 2006-002695-17 A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week in t... bad-data
Reported results 2006-005161-18 A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneaous injections of a sustained-release implant of ZT-1 in patients wit... 2009-04-15 due-trials
Reported results 2008-003531-21 A multicenter, randomized, double-blind, placebo-controlled parallel-group phase IIb study of the safety and efficacy of istaroxime over 24 hours at three doses in acute decompensated heart failure pa... 2009-09-04 due-trials
Reported results 2008-004605-34 A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chroni... 2010-09-06 due-trials
Exempt, with results Terminated 2011-005533-39 A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with standard of care in first- and second-line therapy of patients with Stage IIIb or IV Non-s... 2014-11-10 not-yet-due
Exempt, with results 2012-003495-39 A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Subjec... 2012-12-03 not-yet-due
Exempt 2013-000044-25 A Phase I/II randomized study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio1143 combined with concurrent Chemo-Radiation Therapy in patients with lo... not-yet-due
Reported results 2014-004655-31 Preoperative window-of-opportunity (WoO) study of Debio 1143 with or without cisplatin (CDDP) in patients with resectable squamous cell carcinoma of the head and neck. Etude pré-opératoire explorat... 2018-07-18 due-trials
Trial is outside EEC, and reported results 2015-001607-30 An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonado... bad-data
Reported results 2015-004061-87 A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-H... 2021-06-25 due-trials
Reported results 2015-005137-42 A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer. 2017-11-03 due-trials
Ongoing 2018-003546-16 SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial A dose-optimization, exploratory phase Ib/II study to assess safe... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-003584-53 A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3 2022-01-04 bad-data
Ongoing 2020-000377-25 A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with ... not-yet-due